Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D S Campo

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2008
Coordinated evolution of the hepatitis C virusD S Campo, Z Dimitrova, R J Mitchell, et al.
In Silico Biology|December 4, 2012
Differences in variability of hypervariable region 1 of hepatitis C virus (HCV) between acute and chronic stages of HCV infectionI V Astrakhantseva, D S Campo, A Araujo, et al.
Clinical Pharmacology and Therapeutics|February 4, 2014
Drug resistance of a viral population and its individual intrahost variants during the first 48 hours of therapyD S Campo, P Skums, Z Dimitrova, et al.
In Silico Biology|December 4, 2012
Evaluation of viral heterogeneity using next-generation sequencing, end-point limiting-dilution and mass spectrometryZ Dimitrova, D S Campo, S Ramachandran, et al.
In Silico Biology|December 4, 2012
Coordinated evolution of the hepatitis B virus polymeraseD S Campo, Z Dimitrova, J Lara, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Proceedings of the National Academy of Sciences of the United States of America|July 16, 2008
Coordinated evolution of the hepatitis C virusD S Campo, Z Dimitrova, R J Mitchell, et al.
In Silico Biology|December 4, 2012
Differences in variability of hypervariable region 1 of hepatitis C virus (HCV) between acute and chronic stages of HCV infectionI V Astrakhantseva, D S Campo, A Araujo, et al.
Clinical Pharmacology and Therapeutics|February 4, 2014
Drug resistance of a viral population and its individual intrahost variants during the first 48 hours of therapyD S Campo, P Skums, Z Dimitrova, et al.
In Silico Biology|December 4, 2012
Evaluation of viral heterogeneity using next-generation sequencing, end-point limiting-dilution and mass spectrometryZ Dimitrova, D S Campo, S Ramachandran, et al.
In Silico Biology|December 4, 2012
Coordinated evolution of the hepatitis B virus polymeraseD S Campo, Z Dimitrova, J Lara, et al.
Pageof 1